Molecules 2008, 13
787
1
3-(4-Bromophenyl)-4(3H)-quinazolinone (4f). IR νmax: 1692, 1605, 1456; H-NMR: δ = 8.43 (d, J =
13
8.6 Hz, 1H), 8.12 (s, 1H) and 7.95-7.21 (m, 7H); C-NMR: δ = 160.0, 145.3, 134.6, 133.4, 132.7,
131.4, 130.7, 128.5, 128.1, 127.7, 127.6, 127.6 and 127.1; GC/MS : m/z (%) = 302, 300 (M+ ); Anal.
Calcd. for C14H9 BrN2O: C, 55.84; H, 3.01; Br, 26.53; N, 9.30.
1
3-(2,4-Dichlorophenyl)-4(3H)-quinazolinone (4g). IR νmax: 1679, 1610, 1452; H-NMR: δ= 8.13 (d, J
= 7.6 Hz, 1H), 7.95 (s, 1H), 7.85-7.66 (m, 2H), 7.53 (t, J = 7.3 Hz, 1H), 7.38 (d, J = 7.6 Hz, 2H) and
13
7.25 (d, J = 8.6 Hz, 1H); C-NMR: δ= 164.2, 162.8, 147.6, 136.3, 134.2, 132.6, 130.7, 129.5, 128.3,
127.2, 127.8, 124.1 and 123.1; GC/MS : m/z (%) = 291.13 (M+ ); Anal. Calcd. for C14H8 Cl2N2O: C,
57.76; H, 2.77; , Cl, 24.36; N, 9.62.
3-(2,5-Dichlorophenyl)-4(3H)-quinazolinone (4h). IR νmax: 1673, 1604, 1450; 1H-NMR: δ = 8.43 (d, J
= 7.6 Hz, 1H), 8.13 (s, 1H), 7.69-7.72 (m, 2H), 7.50 (t, J = 7.3 Hz, 1H), 7.38 (d, J = 7.6 Hz, 2H), 7.25
13
(d, J = 8.6 Hz, 2H); C-NMR (CDCl3): δ = 165.2, 163.1, 148.8, 141.6, 134.0, 133.1, 130.2, 129.7,
128.3, 128.2, 126.2, 125.7, 123.1 and 123.1; Anal. Calcd. for C14H8 Cl2N2O: C, 57.76; H, 2.77; , Cl,
24.36 ; N, 9.62.
1
3-(2,6-Dichlorophenyl)-4(3H)-quinazolinone (4i). IR νmax: 1660, 1618, 1456; H-NMR: δ = 8.23 (d, J
= 7.6 Hz, 1H), 8.13 (s, 1H), 7.69-7.72 (m, 2H), 7.50 (t, J = 7.3 Hz, 1H), 7.38 (d, J = 7.6 Hz, 2H) ; 7.25
(d, J = 8.6 Hz, 2H); 13C-NMR: δ= 165.2, 163.3, 148.4, 136.6, 133.2, 128.6, 127.6, 127.5, 127.2, 127.0,
126.9 and 123.1; Anal. Calcd. for C14H8 Cl2N2O: C, 57.76; H, 2.77, Cl, 24.36; N, 9.62.
1
3-(3,4-Dichlorophenyl)-4(3H)-quinazolinone (4j). IR νmax: 1687, 1625, 1461; H-NMR: δ = 8.23 (d, J
= 7.6 Hz, 1H), 8.18 (s, 1H), 7.69-7.72 (m, 2H), 7.50 (t, J = 7.3 Hz, 1H), 7.38 (d, J = 7.6 Hz, 2H) and
13
7.25 (d, J = 8.6 Hz, 2H); C-NMR: δ = 165.2, 163.3, 147.8, 137.7, 134.4, 133.2, 130.7, 130.0, 128.6,
127.1, 127.0, 122.2, 122.1 and 119.9; Anal. Calcd. for C14H8 Cl2N2O: C, 57.76; H, 2.77; Cl, 24.36; N,
9.62.
References and Notes
1. Pereira, M. F.; Chevrot, R.; Rosenfeld, E.; Thiery, V.; Besson, T. Synthesis and evaluation of the
antimicrobial activity of novel quinazolinones. J. Enzym. Inhib. Med. Chem. 2007, 22, 577-583.
2. Kacker, I. K.; Zaheer, S. H. Potential analgesics.1. Synthesis of substituted 4-quinazolinones. J.
Indian Chem. Soc. 1951, 28, 344-346.
3. Brumas, B. V.; Fiallo, M. M. L.; Berthon, G. Copper(II) interactions with non-steroidal anti-
inflammatory reagents. J. Inorg. Biochem. 2006, 100, 362-373.
4. Tamaoki, S.; Yamauchi, Y.; Nakano, Y.; Sakano, S.; Asagarasu, A.; Sato, M. Pharmacological
properties of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl) piperazin-1-yl]butyl}quinazolin-
4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel
syndrome (IBS) and its effects on an experimental IBS model. J. Pharm. Exp. Ther. 2007, 322,
1315-1323.
5. Welch, W. M.; Ewing, F. E.; Huang J.; Menniti, F.S.; Pagnozzi, M. J.; Kelly, K.; Seymour, P. A.;
Guanowsky, V.; Guhan, S.; Guinn, M. R.; Critchett, D.; Lazzro, J.; Ganong, A. H. ; DeVries, K.